Levofloxacin Kabi

Levofloxacin, the active ingredient in Levofloxacin Kabi, is a fluoroquinolone presented as an injectable solution for intravenous use. It provides broad‑spectrum antibacterial activity and is employed to treat serious bacterial infections in adults and children when oral therapy is not appropriate.

GNH USA supplies Levofloxacin Kabi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Levofloxacin Kabi is a fluoroquinolone antibiotic used for a range of serious bacterial infections. - Community‑acquired pneumonia: achieves rapid bacterial eradication to resolve pulmonary infection. - Complicated urinary tract infections: eliminates pathogenic organisms causing upper urinary tract disease. - Complicated intra‑abdominal infections: provides bactericidal activity against mixed aerobic and anaerobic flora. - Skin and soft tissue infections: clears infection in deep or extensive dermal lesions. - Acute bacterial sinusitis: reduces sinus mucosal inflammation by killing the causative bacteria.

Levofloxacin Kabi may cause a variety of adverse reactions, ranging from mild to severe.

Common Side Effects: - Nausea: mild to moderate upset stomach. - Diarrhea: watery stools, sometimes with abdominal cramping. - Headache: transient tension‑type headache. - Dizziness: occasional light‑headed sensation. - Rash: erythematous skin eruption. - Elevated liver enzymes: transient increase in ALT/AST.

Serious or Rare Side Effects: - Tendon rupture: especially Achilles tendon, may occur during or after therapy. - QT interval prolongation: risk of ventricular arrhythmias. - Clostridioides difficile infection: severe colitis following disruption of gut flora. - Anaphylaxis: acute, potentially life‑threatening allergic reaction. - Stevens‑Johnson syndrome/toxic epidermal necrolysis: severe mucocutaneous blistering. - Hepatic failure: rare but may present with jaundice and coagulopathy.

Levofloxacin Kabi requires careful assessment of patient‑specific factors before use. - Renal function: adjust dosing in patients with impaired clearance. - Central nervous system effects: monitor for seizures or confusion, especially in the elderly. - Cardiac risk: avoid in patients with known QT prolongation or arrhythmias. - Drug interactions: review concomitant medications for potential additive toxicity. - Pregnancy and lactation: use only if the expected benefit justifies the potential risk. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Levofloxacin Kabi can interact with several medicines, necessitating vigilance.

Major Interactions (Avoid): - Concurrent fluoroquinolones: increased risk of tendon toxicity. - QT‑prolonging agents (e.g., macrolides, antiarrhythmics): heightened arrhythmia risk. - Systemic corticosteroids: amplified chance of tendon rupture.

Moderate Interactions (Monitor Closely): - Warfarin: may enhance anticoagulant effect; monitor INR. - Theophylline: levofloxacin can raise plasma theophylline levels; watch for toxicity. - Cyclosporine: may increase levofloxacin concentrations; adjust dose if needed.